Japan Sets Conflict Rules For Outside Drug Reviewers
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japan's Pharmaceuticals and Medical Devices Agency's advisory council decided Oct. 1 to formally introduce conflict-of-interest prevention rules, including a cap on consultation and other fees that PMDA-registered outside experts receive from pharmaceutical manufacturers
You may also be interested in...
Four On Japanese Panel Say AstraZeneca Paid After Iressa Decision
Another physician has admitted in a Japanese court case that he received more than $166,000 from AstraZeneca after sitting on a board that endorsed the drug maker's Iressa (gefitinib). The former professor of a private university was among 10 doctors on the board, four of whom have testified so far they received payments. The Tokyo trial involves a suit against the firm and the government brought by families of patients who died of side effects after taking the lung cancer drug. The Ministry of Health, Labor and Welfare has asked the Japan Lung Cancer Society to re-evaluate Iressa's safety. (Click here for more
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).